Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

The new drug, amycretin, similar to the company's blockbuster weight ... Ozempic, provided weight loss of up to 22% in ...

Virta Health has prescribed GLP-1 medications like Ozempic for diabetes since the ... the drugs have exploded for their weight-loss potential. However, previous clinical research has shown that ...

or the maximum tolerated dose, daily by subcutaneous injection) or placebo for 56 weeks. The mean change in BMI was −5.8% with liraglutide and –1.6% with placebo. A recently published observational ...